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Abstract
Background: Although performance measurement for assessing care quality is an emerging area, a system for
measuring the quality of cancer care at the hospital level has not been well developed. The purpose of this study
was to develop organization-based core measures for colorectal cancer patient care and apply these measures to
compare hospital performance.
Methods: The development of core measures for colorectal cancer has undergone three stages including a
modified Delphi method. The study sample originated from 2004 data in the Taiwan Cancer Database, a national
cancer data registry. Eighteen hospitals and 5585 newly diagnosed colorectal cancer patients were enrolled in this
study. We used indicator-based and case-based approaches to examine adherences simultaneously.
Results: The final core measure set included seventeen indicators (1 pre-treatment, 11 treatment-related and 5
monitoring-related). There were data available for ten indicators. Indicator-based adherence possesses more
meaningful application than case-based adherence for hospital comparisons. Mean adherence was 85.8% (79.8% to
91%) for indicator-based and 82.8% (77.6% to 88.9%) for case-based approaches. Hospitals performed well (>90%)
for five out of eleven indicators. Still, the performance across hospitals varied for many indicators. The best and
poorest system performance was reflected in indicators T5-negative surgical margin (99.3%, 97.2% - 100.0%) and
T7-lymph nodes harvest more than twelve(62.7%, 27.6% - 92.2%), both of which related to surgical specimens.
Conclusions: In this nationwide study, quality of colorectal cancer care still shows room for improvement. These
preliminary results indicate that core measures for cancer can be developed systematically and applied for internal
quality improvement.
Background
Colorectal cancer ranks as the third cause of cancer
deaths in the United States and the fourth cause
worldwide [1,2]. Thanks to improvements in diagnostic
and surgical modalities as well as the advancement of
chemotherapy and radiotherapy, many colorectal can-
cer patients do survive more than five years. The five-
year relative survival rate rose from 51% two decades
ago to 65% in recent years [2]. Still there are concerns
about the quality of clinical practice since evidence has
shown discernible variations for patients with similar
conditions [3-5]. Evidence suggests that underuse and
overuse of care may occur for patients with cancer [4].
Also, compared with the outcomes of patients in clini-
cal trials, the outcomes of cancer patients in daily
practice may be less favorable [6,7]. Research on the
quality of care throughout at least the last decade has
demonstrated that increases in the knowledge of treat-
ments with proven efficacy do not translate directly to
the optimal delivery of such treatments to patients
[6,8].
Promoted by the Institute of Medicine, USA, the field
of quality measurement has been growing rapidly along
with accumulation of experience and knowledge in the
cancer care quality area [9]. Core measures, introduced
* Correspondence: kpchung@ntu.edu.tw
1Graduate Institute of Health Care Organization Administration, College of
Public Health, National Taiwan University, Taipei, Taiwan
Chung et al. BMC Health Services Research 2010, 10:27
http://www.biomedcentral.com/1472-6963/10/27
© 2010 Chung et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.by the Joint Commission on Accreditation of Healthcare
Organizations, use standardized sets of valid, reliable
and evidence-based “core” measures that have been
incorporated in quality measurement and performance
improvement systems as well as the accreditation pro-
cess for several diseases [10,11]. There are several
groups who have previously developed measures for col-
orectal cancer [12]. Yet, the studies regarding measure-
ment of cancer quality of care based on a national
database are scarce and we know of no published stu-
dies related to core measures for cancer. Having a single
set of measures for the entire country is the only way to
set national benchmarks and compare countries that
have national programs [13]. Our research team adopted
the concept of core measures to assess the quality of
care provided to patients with breast cancer, colorectal
cancer, cervical cancer, lung cancer, oral cancer and
hepatocellular carcinoma in Taiwan.
H e a l t hi n s u r a n c ei nT a i w a ni sp r o v i d e dw i t h i nas i n -
gle payer system that has covered over 96% of the
population since 1995 [14]. Following the Cancer Pre-
vention and Management Law, a revised cancer registry,
the Taiwan Cancer Database (TCDB) was created in
2003 [15]. The Bureau of Health Promotion (BHP) in
the Department of Health financially supported 27 hos-
pitals (initially 17 major hospitals) to join the TCDB
program with the prerequisite that each hospital is
required to provide cancer prevention, cancer screening,
diagnosis and treatment of cancer, education and clini-
cal audits, and cancer research as well as a quality
assessment system [16]. The TCDB is a nationwide
oncology outcomes database that currently covers
approximately 60% of six new invasive cancer diagnoses
in Taiwan each year. Like its counterpart, the National
Cancer Data Base (NCDB) in the USA, the TCDB is a
large, powerful database providing multiple opportu-
nities for clinical studies and can be used to benchmark
hospitals on performance measures–an impetus for
quality improvement initiatives at the hospital level [17].
Each hospital that voluntarily participates must submit
data twice a year for six types of cancers that men-
tioned above. The prevalence of each disease is increas-
ing, motivating public interest in cancer care quality
nationwide. The core cancer measures were developed
in parallel with the TCDB program through a govern-
ment grant as a national initiative for cancer care
quality improvement [15]. Although performance mea-
surement for assessing care quality is booming, a system
for measuring the quality of cancer care at the hospital
level has not been well developed. The purpose of this
study was to develop organization-based core measures
for colorectal cancer patient care and apply these mea-
sures to compare hospital performance.
Methods
Patients and hospitals
The patients and hospitals registered in the TCDB pro-
gram in Taiwan during 2004 were eligible for this study.
Participation in the program is voluntary for each hospi-
tal but the number is increasing each year partly due to
financial incentives. Some information is required in
order to link each cancer registry record to insurance
claims data. Due to problems with the timeliness and
quality of data for nine of the hospitals, eighteen hospi-
tals were selected as the main sources of data for this
study (see Appendix).
Core measures development
The process of core measures development has gone
through a preparation stage, a consensus building stage,
and two rounds of stakeholder feedback (see Figure 1),
similar with our pilot study of breast cancer [16]. This
study was sponsored by a grant (DOH93-HP-1057) and
approved by Review Board of Data Release (equivalent
to Ethics Committee) from the Bureau of Health Pro-
motion, Department of Health, Taiwan. Seven university
faculty members (including Author KPC, SHC, LTC,
RT, TWL, MJS and a scholar) voluntarily constituted
the research team, which held four meetings in the pre-
paration stage. The research team then collaborated
with experts and other stakeholders to develop rigorous,
evidence-based, scientifically sound measures which
could be used as the standards of cancer care quality
nationwide. The search terms used included the Medical
Subject Heading terms ‘outcome and process assessment
health care’, ‘quality indicator health care’, ‘quality of
health care’, ‘practice guidelines’, ‘evidence-based medi-
cine’, ‘colorectal neoplasms’ and the keyword ‘perfor-
mance measures’ from January 1985 to January 2002.
All possible quality-related cancer indicators were sum-
marized (including RAND (Research and Development
Corporation, USA) and National Health Service guide-
lines) [18-30] and reduced to a final measure set via a
modified Delphi method and stakeholder feedback. In
addition to validity and feasibility, indicator selection
was guided by other criteria such as scientific acceptabil-
ity, importance and necessity, and usability [16].
The Delphi group, nominated by the Taiwan Clinical
Oncology Group from the National Health Research
Institute as well as related specialty societies, encom-
passed twenty clinical professionals who represented the
organization of their specialty. Included were four gas-
tro-intestinal physicians, three oncological physicians,
three radiological oncologists, seven colorectal surgeons
and three pathologists (see Appendix). The panel mem-
bers met face-to-face during 2004. Indicators were
anonymously rated on a 9-point scale (with 1 denoting
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Page 2 of 11Figure 1 Design and development of core measure for colorectal cancer. *members of research team included KPC, SHC, LTC, RT, TWL, MJS
and a scholar,
#twenty expert were invited (research team member excluded), see also the expert panel in Appendix,
1 including 37 structure
indicators, 78 process indicators, and 7 outcome indicators,
2 including 9 structure indicators, 37 process indicators, and 4 outcome indicators,
3including 4 pre-treatment indicators, 21 treatment indicators, and 5 monitor indicators,
4including 3 pre-treatment indicators, 16 treatment
indicators, and 6 monitor indicators,
5including 2 pre-treatment indicators, 16 treatment indicators, and 6 monitor indicators,
6including 1 pre-
treatment indicator, 11 treatment indicators, and 5 monitor indicators,
7hospitals and clinical professionals are major stakeholders,
8questionnaires
were mailed on August 16, 2004, response rate 95% (19/20),
9 expert meeting was held in Taipei, September 22, 2004,
10 questionnaires were
mailed on October 26, 2004, response rate 85% (17/20),
11 1
st symposium was held in Taipei, December 27, 2005,
12 2
nd symposium was held in
Taipei, March 27, 2006.
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Page 3 of 11not valid and 9 very valid) and only indicators with a
median score of 7 or higher were selected as final candi-
date indicators. After initial analysis of the panel data,
the expert panel and stakeholders from different hospi-
tals met on March 27, 2006 to review and streamline
the indicators.
Comparisons across hospitals
Currently, the emphasis on quality measurement in clini-
cal, including cancer, care is on evaluating adherence to
“evidence-based” process measures. This quantitative
approach to quality improvement moves the field forward
by ranking quality measures according to both quantitative
assessment of under-performance across institutions and
the measures’ potential impact on outcomes [31]. Reeves
et al. recently summarized five methods for computing a
composite quality score including “Indicator Average” and
“Patient Average” [32], both of which we used in this
study to derive adherence across hospitals and were desig-
nated as indicator-based and case-based adherence. Indi-
cator-based adherence was derived from “all the care
received in a given hospital for a specific indicator” divided
by “all the care recommended in a given hospital for that
indicator”. Case-based adherence was computed as the
percentage of indicators that were successfully met for
each patient. These percentages were then averaged across
all patients in a given hospital. To compare hospitals,
three different scenarios were adopted. In the first sce-
nario, each hospital was awarded one point for each indi-
cator in which adherence to criteria was greater than the
50
th percentile. These points were then added to form a
hospital score. Similar procedures were followed for Sce-
narios 2 and 3 except the thresholds were set at the 75
th
and 90
th percentiles respectively. This approach made hos-
pital comparisons an easier task.
Results
Patient and disease characteristics
A total of 5585 patients who had newly diagnosed col-
orectal cancer and complete information regarding
their treatment during 2004 entered into this analysis.
The demographic characteristics are listed as Table 1.
Mean age of the recruited sample was 64 years old.
Males were more prone to have colorectal cancer
(male to female: 58.3% to 41.7%), even in each stage.
More than sixty percent of the patients were older
than sixty years old. Patients younger than 40 years
old comprised only 6% of the study group. By disease
stage, Stage III was the most common stage at the
time colorectal cancer was discovered. It constituted
29.9% of the sample, followed by Stage II (24.9%),
Stage IV (20.6%) and Stage I (14.1%). Carcinoma in
situ was only found in about 3% of the newly diag-
nosed patients (Table 1).
Core measures
The final set of core measures for colorectal cancer
encompassed seventeen indicators belonging to three
groups: one for “Pre-treatment”, eleven for “Treatment”,
and five for “Monitoring”. Table 2 (see Additional file 1
for definition) displays the description, rationale,
numerator, denominator, and evidence level (or grade of
recommendation) for each indicator. However, not all
core measures of colorectal cancer developed in this
fashion were included in this study. All five indicators
for “Monitoring” were excluded due to the constraint of
short study interval. Two indicators (T2 and T8) requir-
ing intensive chart reviews were not also included.
Finally, ten indicators (T3 was divided into T3a, T3b
sub-indicator) could be constructed from attainable data
for colorectal cancer. Nearly all data required were
retrieved from the TCDB with the exception of the T1
indicator, in which partial information was obtained
from claim data.
Hospital performances and comparisons
Hospital performances were displayed as indicator-based
and case-based adherence. To show system performance
for colorectal cancer, the box plots in Figure 2 illustrate
the range of hospital performance with respect to
Table 1 Characteristics of colorectal cancer patients undergoing surgery in 2004 by cancer staging.
Gender Age (years)
Male Female <30 31-40 41-50 51-60 >60 Total
stage 0 97 60 2 7 22 38 88 78(1.4%)*
stage 1 463 324 6 27 65 167 522 787(14.1%)*
stage 2 811 580 15 49 142 229 956 1,391(24.9%)*
stage 3 960 711 14 94 200 340 1023 1,671(29.9%)*
stage 4 633 488 31 61 164 219 676 1,151(20.6%)*
unspecified stage 263 165 10 19 44 75 280 428(7.7%)*
3257
(58.3%)
#
2328
(41.7%)
#
157
(2.8%)
#
257
(4.6%)
#
637
(11.4%)
#
1068
(19.1%)
#
3545
(63.5%)
#
5585 (100%)
* the number in the parenthesis indicates the percentage of each stage (e.g. 1.4%= 78/5585);
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Indicator Description Numerator Denominator Evidence level or
grade of
recommendation
Rationale
PT1 Proportion of colorectal
patients who have pre-
operative chest X-ray and
abdominal ultrasound, CT
scan or MRI
18
Number of colorectal patients
who have pre-operative chest
x-ray and abdominal
ultrasound, CT scan or MRI
(including off-site)
Number of all colorectal
patients
Grade C Comprehensive-
ness of pre-
operative evaluation
T1 Proportion of colorectal
patients who have
undergone surgical resection
for colon or rectal cancer
have documentation that
colonoscopy or barium
enema with sigmoidoscopy
was offered within 6 months
before or after surgery
19,20
Number of colorectal patients
who have undergone surgical
resection for colon or rectal
cancer have documentation
that colonoscopy or barium
enema with sigmoidoscopy
(including off-site) was
offered within 6 months
before or after surgery
Number of colorectal patients
who have undergone surgical
resection for colon or rectal
cancer
Level II-2 Synchronous colon
or rectal cancer
T2* Proportion of colorectal
patients who have
undergone wide surgical
resection for malignant polyp
of colon or rectum within 6
weeks of pathological report
(polypectomy) revealing
incomplete or positive margin
or venous or lymphatic
invasion or poorly
undifferentiated
19
Proportion of colorectal
patients who have
undergone wide surgical
resection for malignant polyp
of colon or rectum within 6
weeks of pathological report
(polypectomy) revealing
incomplete or positive
margin or venous or
lymphatic invasion or poorly
undifferentiated
Number of colorectal patients
who pathological report for
malignant polyp of colon or
rectum revealing incomplete
or positive margin or venous
or lymphatic invasion or
poorly undifferentiated
Level II-2, III Increase curability
T3a Proportion of patients who
are diagnosed with colon
cancer and do not have
metastatic disease were
offered a curative resection
within 6 weeks of diagnosis.
(For patient with diagnosis
and treatment of care in the
same hospital)
19,23
Number of patients who are
diagnosed with colon cancer
and do not have metastatic
disease were offered a
curative resection within 6
weeks of diagnosis. (For
patient with diagnosis and
treatment of care in the
same hospital)
Number of patients who are
diagnosed with colon cancer
and do not have metastatic
disease. (For patient with
diagnosis and treatment of
care in the same hospital)
Level II-2, III Improve survival
T3b Proportion of patients who
are diagnosed with colon
cancer and do not have
metastatic disease were
offered a curative resection
within 6 weeks of
diagnosis
19,23
Number of patients who are
diagnosed with colon cancer
and do not have metastatic
disease were offered a
curative resection within 6
weeks of diagnosis
Number of patients who are
diagnosed with colon cancer
and do not have metastatic
disease
Level II-2, III Improve
Survival
T4 Proportion of stage I to III
colorectal patients who have
histopathology reports which
give the degree of
involvement of surgical
margins, including
circumferential margins, the
number of lymph nodes
examined and the number
involved
21,
22
Number of stage I to III
colorectal patients who have
histopathology reports which
give the degree of
involvement of surgical
margins, including
circumferential margins, the
number of lymph nodes
examined and the number
involved
Number of stage I to III
colorectal patients excluding
patients undergo
polypectomy
Grade B Provide information
for subsequent
intervention, which
related to tumor
recurrence
T5 Proportion of stage I to III
colorectal patients who
undergo a wide surgical
resection that have
documented to be “negative
margins”
19,23
Number of stage I to III
colorectal patients who
undergo a wide surgical
resection that have
documented to be “negative
margins”
Number of stage I to III
colorectal patients excluding
no pathological report
regarding status of margin
Level II-2, III Radical excision
T6 Proportion of colorectal
patients who undergo a
surgery that have a pathology
report with the information
on tumor size and node
differentiation
22,24
Number of colorectal patients
who undergo a surgery that
have a pathology report with
the information on tumor
size and node differentiation
Number of colorectal patients
who undergo a surgery
Class B Provide information
for subsequent
intervention and
follow-up
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Page 5 of 11Table 2: Core measure indicators for colorectal cancer (Continued)
T7 Proportion of I to III stage
colorectal cancer patients
with twelve or more lymph
nodes on pathology report
25
Number of I to III stage
colorectal cancer patients
with twelve or more lymph
nodes on pathology report
Number of I to III stage
colorectal cancer patients
excluding polypectomy, or
neo-radiotherapy
Level III or IV Radical excision and
pathological
accountability
T8* Proportion of pathological
report according to CAP
checklist or similar one
21,26
Number of pathological
report according to CAP
checklist or similar one
Number of colorectal patients Pathological report
comprehensiveness
T9 Proportion of stage III colon
cancer patients who was
offered chemotherapy within
6 weeks after surgery
19,27,28
Number of stage III colon
cancer patients who was
offered chemotherapy within
6 weeks after surgery
Number of stage III colon
cancer patients who was
offered chemotherapy after
surgery (in the same hospital)
Level I, II-2, III Increase
Survival
T10 Proportion of patients who
are diagnosed with Stage II
or III rectal cancer, was
offered treatment including
surgery, radiotherapy, or CCRT
treatment within 6 weeks of
diagnosis
19,24
Number of patients who are
diagnosed with Stage II or III
rectal cancer, was offered
treatment including surgery,
radiotherapy, or CCRT
treatment within 6 weeks of
diagnosis
Number of patients who are
diagnosed with Stage II or III
rectal cancer, was offered
treatment in the same
hospital
Level II-2, III Avoid treatment
delay
T11 Proportion of patients who
are diagnosed with rectal
cancer that appears clinically
to be Stage II or III, and was
offered surgical resections
within 16 weeks after
beginning of CCRT
19,23
Number of patients who are
diagnosed with rectal cancer
that appears clinically to be
Stage II or III, and was offered
surgical resections within 16
weeks after beginning of
CCRT
Number of patients who are
diagnosed with rectal cancer
that appears clinically to be
Stage II or III, and was offered
CCRT before surgery
Level II-2, III Provide treatment
for cure intent
F1* Proportion of patients who
had completed all courses of
therapy for Stage I to III
lesions had medical check-up
again within 6 months of
completion
19,29
Number of patients who had
completed all courses of
therapy for Stage I to III
lesions had medical check-up
again within 6 months of
completion
Number of patients who had
completed all courses of
therapy for Stage I to III
lesions
Level II-2, III Decrease mortality
F2* Proportion of patients who
had completed surgery for
Stage I to III lesions had
medical check-up again
including colonoscopy or LGI
series within 2 years period
and subsequent 3 years
interval
19
Number of patients who had
completed surgery for Stage I
to III lesions had medical
check-up again including
colonoscopy or LGI series
within 2 years period and
subsequent 3 years interval
Number of patients who had
Stage I to III lesions
Level II-2, III Decrease recurrence
F3* Proportion of patients who
are treated by polypectomy
procedure for malignant
polyp was offered
colonoscopy within 12
months of procedure
19,30
Number of patients who are
treated by polypectomy
procedure for malignant
polyp was offered
colonoscopy within 12
months of procedure
Number of patients who are
treated by polypectomy
procedure for malignant
polyp
Level III Decrease recurrence
F4* Five-year over-all survival rate,
stage specific (Stage I to IV)
28
Number of patients who
survive at five-year period,
stage specific (Stage I to IV)
Number of patients, stage
specific (Stage I to IV)
Class C Assess survival
F5* Five-year local recurrence
rate, stage specific (Stage I to
III)
18
Number of patients who had
recurrence at five-year period,
stage specific (Stage I to III)
Number of patients, stage
specific (Stage I to III)
Grade B Assess recurrence
*: indicators excluded in the results due to data un-available.
1. Stage I to IV are based on classification of TNM system, AJCC (the American Joint Committee on Cancer);
2. Level I, Level II-2, Level III and Level IV: adopted from RAND
19, Desch
29; Class B: adopted from SIGN 2003
22; Class C: adopted from Guideline 2001
28; Grade B
and Grade C: adopted from RCSI 2002
18; see Additional file 1 for definition.
3. PT: pre-treatment; T: treatment; F: follow-up; CT: computed tomography; MRI: magnetic resonance imaging; CAP: College of American pathology; CCRT:
concurrent chemo-irradiation; LGI series: Lower gastrointestinal series.
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Page 6 of 11indicator-based adherence. From this informative plot,
we learned how good or how bad our hospitals per-
formed with respect to each indicator–the display helps
make explicit which indicators might be improved. Five
indicators (45% or 5/11) in this plot had mean adher-
ence greater than 90% (T4: 98.3%, T5:99.3%, T6: 97.6%,
T10: 91.8%, T11: 96.8%). Still, there were many indica-
tors showing a wide range of performance. We also note
that two indicators had mean adherence less than 70%
(T1 66.6%, 36.6% to 85.0%; T7: 62.7%, 27.6% to 92.2%).
The best and poorest system performance occurred for
T5-negative surgical margin (99.3%, ranged from 97.2%
to 100.0%) and T7-lymph nodes harvest more than
twelve (62.7%, ranged from 27.6% to 92.2%). Both indi-
cators relate to surgical specimens.
T a b l e3s u m m a r i z e st h ed e t a i l so fa d h e r e n c et ot h e
core measures and hospital scores for inter-hospital
comparisons. Data were presented as means, 95 per-
cent confidence intervals and ranges as indicated.
Then we displayed results in a table of inter-hospital
comparisons. Adherence to indicator-based and case-
based approaches for each hospital ranged from 79.8%
to 91.0% and 77.6% to 88.9%, respectively. Results of
indicator-based approach are always larger than case-
based approach except for one hospital (H06). On
average, patients received 85.8% of recommended care
for indicator-based adherence, and 82.8% for case-
based adherence. The three different scenarios of hos-
pital scoring methods could only be applied to indica-
tor-based adherence. The average hospital scores were
5 . 3( 2t o8 ) ,3 . 5( 0t o6 ) ,a n d2 . 2( 0t o4 )w i t hr e s p e c t
to the 50
th,7 5
th,a n d9 0
th percentiles respectively. Hos-
pital rankings were not consistent among the three
methods. Adoption of alternative methods of aggregat-
ing scores can lead to different interpretations.
Discussion
The core measures for colorectal cancer discussed in this
study are one of the six cancer-specific sets of indicators
developed in a government-sponsored program with
scoring technique improvements, larger expert participa-
tion. Refinement of core measures development from our
prior study of breast cancer included: 1. expand the num-
ber of Delphi panelists from seven to twenty; 2. adopt the
RAND Appropriateness technique (scale 1 to 9) to select
indicators from previously developed technique (scale 1
to 5, median equal or greater than four and 86% agree-
ment threshold) [5]; 3. change threshold for selecting
indicators to a score of seven or higher. More stake-
holders’ participation and discussion during stakeholder
feedback symposium suggest enthusiasm and the com-
mitment of healthcare professionals in the development
of methods for quality improvement in colorectal cancer
care. However, the level of evidence for indicators could
not match those of the pilot study we developed pre-
viously for breast cancer, which included six level I, four
level II and five level III recommendations. Nevertheless,
it is our belief that these measures represent a valuable
contribution to the growing library of clinical cancer
measures which can be used for public awareness, poten-
tial improvement and accreditation standards for cancer
care centers or specialty groups.
A n yn e wp e r f o r m a n c em e a s u r es e t ,i n c l u d i n gt h e
current cancer core measure sets, frequently encounter
a major hurdle, i.e. data resources. It would be easier if
the information needed to construct measures came
Figure 2 Box-plot illustrates hospital’s adherence for each core measure indicator (indicator-based) of colorectal cancer. Mean of five
indicators (T4, T5, T6, T10, T11) had adherence greater than 90%. PT: pre-treatment, T: treatment.
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Page 7 of 11from ICD-9 codes of a billing system. But actually for
cancer care research, requirements include the stage,
tumor size, node numbers, and status of section mar-
gins, none of which are captured in claim-based sys-
tems. Although these data are available in medical
records, such detailed review of charts on a national
scale would be cumbersome and expensive [33]. The
TCDB program solved this dilemma; its establishment
was the result of the increasing demands for research
that would help inform reporting and pay for perfor-
mance systems. Breast cancer was the first disease
entity undertaken by the TCDB program. The number
of newly diagnosed breast cancers represented 81.4%
of all new cases in 2004, partly due to greater efforts
in reporting. Reports of colorectal cancer didn’tc a t c h
up this pace, but finally we identified 5585 patients
newly diagnosed in 2004 within the TCDB. This sam-
ple accounted for 58.6% (5585/9535) of all newly diag-
nosed patients with cancer that occurred in Taiwan
that year. We consider this sample representative of
the population who has been and is being treated for
colorectal malignancy in this country. The scope of the
T C D Bp r o g r a mw i l lh o p e f u l l ye x t e n dt oa l lt y p e so f
cancer in the future and will continue to provide feed-
back to participating hospitals.
Our results suggest that patients with colorectal can-
cer receive 86% (indicator-based adherence) and 83%
(case-based adherence) of recommended care. Adher-
ence to four indicators approached 100%, indicating that
excellent quality of care is accomplishable. Yet, we
observed four indicators with less than 85% adherence,
and for these indicators, there was substantial variability
in quality across hospitals. The adherence to twelve core
measures for breast cancer in our prior report was infer-
ior (65.8%, indicator-based).
Our results can be compared with a growing literature
that describes the quality of cancer care, as well as stu-
dies that describe care quality of chronic conditions. For
example, results of the National Initiative for Cancer
Care Quality (NICCQ) showed that patients with breast
cancer receive 86% of recommended care, whereas
patients with colorectal cancer receive 78% of recom-
mended care [3]. Using a methodology similar to that of
NICCQ, two national studies suggest that the quality of
c a r ef o rc a n c e rm a yb es i m i l a ro rb e t t e rt h a nt h a t
observed for other chronic medical conditions. Jencks et
al. reported 73% of Medicare beneficiaries received
health care services specified by one of 24 quality mea-
sures addressing heart disease, stroke, and pneumonia
[34]. Another study by McGlynn et al. concluded that
Table 3 Results of organizational performance of colorectal cancer care by core measure indicators
Hospitals\Performance Indicator-based Case-based
Adherence
1* Hospital score
1# Hospital score
2# Hospital score
3# Adherence
2*
% (95 CI) % (95 CI)
H01
§ 86.5 (79.4-93.7) 5 2 2 83.5 (80.4-86.7)
H02 87.1 (79.3-95.0) 5 5 2 84.2 (82.4-86.0)
H03 82.3 (68.9-95.8) 6 4 2 79.8 (76.7-82.9)
H04 82.4 (70.3-94.6) 5 4 4 79.7 (77.2-82.1)
H05 88.8 (82.2-95.4) 7 3 1 86.1 (82.7-89.5)
H06 85.7 (76.3-95.1) 6 4 4 88.1 (85.3-90.9)
H07 90.2 (83.0-97.4) 8 6 4 85.6 (82.3-89.0)
H08 91.0 (83.2-98.7) 8 6 3 88.9 (87.8-90.1)
H09 85.9 (77.5-94.3) 4 3 1 81.2 (78.5-83.9)
H10 86.1 (78.2-94.0) 6 4 4 84.7 (82.6-86.9)
H11 79.8 (67.7-91.9) 2 0 0 79.4 (77.5-81.3)
H12 84.7 (75.0-94.5) 4 1 1 82.2 (79.7-85.3)
H13 88.9 (82.1-95.7) 6 4 2 84.1 (80.4-87.7)
H14 85.3 (76.3-94.2) 6 6 3 85.4 (82.6-88.1)
H15 82.4 (74.1-90.7) 3 0 0 80.7 (78.4-83.1)
H16 81.8 (71.3-92.4) 4 4 2 77.6 (73.0-82.1)
H17 85.0 (73.8-96.1) 6 3 2 78.7 (75.1-82.3)
H18 86.6 (76.9-96.3) 5 4 3 81.6 (79.6-83.7)
Mean 85.8 (78.3-93.3) 5.3 3.5 2.2 82.8
*: Adherence
1(Indicator-based adherence); Adherence
2 (case-based adherence); 95 CI (95% confidence interval) listed in the parenthesis
#: Hospital score are composite score for indicator-based level, defined as following: one point was awarded if adherence >50
th percentile (Hospital score
1)o r
>75
th percentile (Hospital score
2)o r>9 0
th percentile (Hospital score
3) for each indicator, and then sum up.
§: H01 to H18 denote the corresponding hospital (H). We report the results by designation to maintain the confidentiality of the hospitals and providersw h o
participated in TCDB.
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received approximately 55% of recommended care for
thirty acute and chronic conditions according to the
results from a nation-wide telephone survey [5]. But in
that study, they reported 53.9% (95% CI, 45.7-60.4)
adherence to twelve quality indicators for colorectal
cancer.
Indicator-based adherence is another issue that must
be discussed. Since the quality measurement of cancer
care is emerging, few studies have reported results of
hospital adherence for each indicator. Adherence mea-
sured by four indicators in our results (T1-diagnostic
evaluation, T3b-surgery, T7-pathological reporting, T9-
adjuvant therapy) were less than 85%. In contrast, all
diagnostic evaluation, adjuvant therapy (but not sur-
gery), and pathological reporting in the NICCQ showed
adherence less than 85% [3]. Another unexpected find-
ing is the adherence to indicator T9, the only indicator
with Level I evidence support, was less than 85%
(77.4%). Of note, we explored the best (T5) and poorest
(T7) adherence for system performance, which might
suggest that surgeons did well to achieve safety margins
for cancer specimens but failed to remove more than
twelve lymph nodes as recommended. But actually there
are three major influences on the total number of nodes
harvested: the surgeon, with regards to technique and
philosophy; the pathologist, with regard to specimen
evaluation technique (fat clearing or cherry-picking) and
philosophy; and patient characteristics, with regard to
tumor site, T stage, immune response, and age [35]. A
study by Bilimoria et al. lamented that more than 60%
of US institutions failed to achieve a compliance bench-
mark for the 12-node measure and called for efforts
aimed at improvement in colon cancer nodal evaluation
[36]. According to their benchmark (examination of ≥12
nodes in ≥75% of patients), we had as much as 72% (13/
18) of institutions that failed such a benchmark and
actually this percentage might be under-estimated for
the daily practice for all cancer care in Taiwan.
Improvement should be encouraged for these controlla-
ble factors.
Two different types (indicator-based and case-based)
of adherence have been presented in this organizational
level study. Results of case-based adherence and indica-
tor-based adherence were similar (usually slightly smal-
ler for case-based). But it seems there may be more
practical applications for indicator-based adherence
since as shown in Table 3, indicator-based adherence
can provide more details in terms of potential improve-
ments to be considered than case-based adherence. The
box-plot in Figure 2 was also created according to the
indicator-based adherence methodology. For quality
comparisons at the organizational level, we would sug-
gest indicator-based adherence measures, which provide
more needed information on quality improvement than
case-based adherence.
Individual quality measures have significant limitations
for assessing performance. Despite growing interest in
composite measures, methods for combining multiple
domains of surgical quality are not well established [37].
Composite scores are an aggregation of underlying per-
formance indicators into a single index and have been
used widely in the public sector to create one more
easily understood number or rating [38,39]. But in com-
bining quality indicators to rank hospitals, how one
aggregates quality measures for easy understanding is
still disputable. Following the criterion-referenced
method, we arbitrarily used three different thresholds to
rank performance of participating hospitals. Composites
are bedeviled by questions of weighting [30]. All weight-
ing systems are arbitrary, and equal weighting is trans-
parent even if it is indefensible at the margins [40]. In
the current study, every opportunity to deliver recom-
mended care is weighted equally. However, with equal
weighting, quality measured by a composite could seem
high even if rare but critical processes were lethally
unsafe. Given the increasing use of composites, research
is needed to define which indicators can legitimately be
made into composites, to develop and test clear ratio-
nales for weighting schemes, and to build understanding
of how changing weights alters conclusions about per-
formance [41].
As quality measures are gaining momentum in the
healthcare industry, our findings have important impli-
cations for health policy. The core measures can be
used for internal improvement of cancer care in the
near future. Also, core measures may provide account-
ability for the basis of pay-for-performance systems and
public reporting, as well as for accreditation.
Several limitations of this study should be discussed.
First, the database of this study was secondary data.
Although the personnel of the cancer registry for each
organization have undergone accreditation and continu-
ous education, we cannot overlook the possibilities of
mistyping or underreporting. Second, only hospitals par-
ticipating in the project reported to the TCDB. These
hospitals may exhibit a higher level of specialization
than hospitals that are not in the project. If we com-
bined reporting and non-reporting hospitals, the differ-
ences in adherence would likely be increased. Third, we
focused more on the effectiveness aspect of quality,
while other aims for improvement such as safety and
patient-centered care were not considered simulta-
n e o u s l y[ 4 2 ] .F i n a l l y ,a sw em e n t i o n e de a r l i e r ,t h ee v i -
dence level for colorectal cancer doesn’t parallel that
available for breast cancer which limits the study’s gen-
eralizability. Research studi e ss u c ha sr a n d o m i z e dc l i n i -
cal trials of cancer care should be encouraged in the
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Page 9 of 11future to enhance the evidence level of research on col-
orectal cancer care.
Conclusions
Standardized performance measurement is an emerging
methodology for comparing health care quality among
different facilities. To the best of our knowledge, this is
t h ef i r s ts t u d yo nc o l o r e c t a lc a n c e rc a r eq u a l i t yb a s e d
on core measures with a nationwide database. Develop-
ing core measures for cancer care is the first step to
achieving standardized measures for external monitor-
ing, as well as for providing feedback and serving as
benchmarks for cancer care quality improvement. By
applying a core measures approach more comprehen-
sively in this fashion, hopefully we can expect to stan-
dardize clinicians’ daily practice as well as reduce care
disparities and improve outcomes for the general popu-
lation. Future research may capture opportunities to
improve cancer care quality by including perspectives
from patients, physicians and systems as well as the
relationships between core measures and outcomes.
Appendix
1. Expert panel members and affiliations:
￿ M D ,P h D ,P r o f e s s o r ,D e p a r t m e n to fM e d i c i n e ,
National Taiwan University Hospital;
￿ MD, PhD, Associate Professor, Department of Sur-
gery, National Taiwan University Hospital;
￿ MD, PhD, Department of Radiation Oncology,
National Taiwan University Hospital;
￿ MD, PhD, Professor, Department of Colorectal Sur-
gery, Taipei Veteran General Hospital;
￿ MD, Department of Radiation Oncology, Taipei
Veteran General Hospital;
￿ MD, Director, Department of Colorectal Surgery,
Taichung Veteran General Hospital;
￿ MD, Professor, Director, Department of General
Surgery, Tri- Service General Hospital;
￿ MD, Associate Professor, Director, Department of
Radiology, Tri- Service General Hospital;
￿ MD, Director, Department of Oncology, Taipei
Mackay Memorial Hospital;
￿ MD, PhD, Associate Professor, Director, Department
of Oncology, Far Eastern Memorial Hospital;
￿ MD, Director, Department of Internal Medicine,
Taipei Cathy General Hospital;
￿ MD, Director, Department of Pathology, Taipei
Cathy General Hospital;
￿ M D ,P h D ,D e p a r t m e n to fo n c o l o g y ,C h u n g - G u n g
Memorial Hospital;
￿ MD, PhD, Professor, Director, Department of Color-
ectal Surgery, Chung-Gung Memorial Hospital;
￿ MD, PhD, Professor, Director, Department of Medi-
cine, Chung-Gung Memorial Hospital;
￿ MD, PhD, Associate Professor, Director, Department
of Oncology, Chung-Gung Memorial Hospital;
￿ M D ,P h D ,P r o f e s s o r ,D i r e c t o r ,D e p a r t m e n to fS u r -
gery, National Chen-Gung University Hospital;
￿ M D ,P h D ,P r o f e s s o r ,D i r e c t o r ,D e p a r t m e n to f
Pathology, National Chen-Gung University Hospital;
￿ MD, Director, Department of Internal Medicine,
Kaohsiung Medical University Hospital;
￿ MD, PhD, Director, Department of Oncology,
Chung-Gung Memorial Hospital.
2. Hospital enrolled in the context including:
￿ National Taiwan University Hospital;
￿ National Chen-Gung University Hospital;
￿ Taipei Veteran General Hospital;
￿ Taichung Veteran General Hospital;
￿ Kaohsiung Veteran General Hospital;
￿ Taipei Mackay Memorial Hospital;
￿ Tri- Service General Hospital;
￿ Koo Foundation Sun Yet-Sen Cancer Center;
￿ Buddhist Tzu Chi General Hospital, Da-Lin Branch;
￿ Taipei Cathy General Hospital;
￿ Shin Kong Wu Ho-Su Memorial Hospital;
￿ Chung-Gung Memorial Hospital;
￿ Chung-Gung Memorial Hospital, Kaohsiung Branch;
￿ China Medical University Hospital, Taiwan;
￿ Changhua Christian Hospital;
￿ Chia-Yi Christian Hospital;
￿ Chi Mei Medical Center;
￿ Kaohsiung Medical University Hospital.
Additional file 1: Levels of evidence or grades of recommendations.
This additional file 1 showed what specifications of evidence levels or
recommendation grades we used during development of core measures.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6963-10-
27-S1.DOC]
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